• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠状动脉内注射链激酶期间纤溶系统的激活。

Activation of the fibrinolytic system during intracoronary streptokinase administration.

作者信息

Six A J, Brommer E J, Müller E J, Kerkhoff H F

出版信息

J Am Coll Cardiol. 1987 Jan;9(1):189-96. doi: 10.1016/s0735-1097(87)80100-6.

DOI:10.1016/s0735-1097(87)80100-6
PMID:3794096
Abstract

Serial biochemical studies were performed in 12 patients treated with intracoronary streptokinase infusion for acute myocardial infarction, in order to study the method of activation of the fibrinolytic system during local administration of a relatively low dose of this drug and to determine correlations between systemic effects and reperfusion. Plasma samples were obtained before and every 15 minutes during the infusion of streptokinase and after completion of the therapy. Streptokinase dosage in this study was 211,000 +/- 88,000 IU (+/- SD). The average time from the onset of symptoms to the start of infusion was 2 hours 50 minutes (range 1 hour 10 minutes to 3 hours 30 minutes). Reperfusion occurred in six patients and temporary recanalization in three; in three patients no recanalization was achieved. Fibrinolytic assays of pretreatment plasma samples revealed elevated levels of plasminogen activators, presumably caused by the release of tissue-type plasminogen activator after a condition of stress. Plasminogen concentrations decreased from 94 +/- 17% to 44 +/- 30%. Alpha 2-antiplasmin fell from 84 +/- 27% to 12 +/- 19%; in seven patients no plasmin inhibitor activity was measurable at the completion of the infusion. Free plasmin occurred in samples only when this inhibitor had disappeared. This resulted in a lytic state leading to degradation of fibrinogen, the levels of which fell from 2.9 +/- 0.7% to 1.5 +/- 1.1%. Fibrinogen degradation products, measured in plasma with monoclonal antibodies, increased exponentially during streptokinase infusion in at least four patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对12例接受冠状动脉内输注链激酶治疗急性心肌梗死的患者进行了系列生化研究,目的是研究在局部给予相对低剂量该药时纤维蛋白溶解系统的激活方法,并确定全身效应与再灌注之间的相关性。在输注链激酶期间,每隔15分钟以及治疗结束后采集血浆样本。本研究中链激酶的剂量为211,000±88,000国际单位(±标准差)。从症状出现到开始输注的平均时间为2小时50分钟(范围为1小时10分钟至3小时30分钟)。6例患者实现再灌注,3例患者出现短暂再通;3例患者未实现再通。治疗前血浆样本的纤维蛋白溶解分析显示纤溶酶原激活剂水平升高,推测是由应激状态后组织型纤溶酶原激活剂的释放所致。纤溶酶原浓度从94±17%降至44±30%。α2-抗纤溶酶从84±27%降至12±19%;7例患者在输注结束时无法检测到纤溶酶抑制剂活性。仅当这种抑制剂消失时,样本中才会出现游离纤溶酶。这导致了一种溶解状态,导致纤维蛋白原降解,其水平从2.9±0.7%降至1.5±1.1%。用单克隆抗体在血浆中检测的纤维蛋白原降解产物在至少4例患者的链激酶输注期间呈指数增加。(摘要截短于250字)

相似文献

1
Activation of the fibrinolytic system during intracoronary streptokinase administration.冠状动脉内注射链激酶期间纤溶系统的激活。
J Am Coll Cardiol. 1987 Jan;9(1):189-96. doi: 10.1016/s0735-1097(87)80100-6.
2
Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency.冠状动脉内注射链激酶对急性心肌梗死和冠状动脉供血不足患者的纤溶作用。
Circulation. 1983 May;67(5):1031-8. doi: 10.1161/01.cir.67.5.1031.
3
Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.急性心肌梗死中静脉注射茴香酰化纤溶酶原链激酶激活剂复合物与冠状动脉内注射链激酶的比较。
Am J Cardiol. 1988 Jul 1;62(1):25-30. doi: 10.1016/0002-9149(88)91359-8.
4
Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.急性心肌梗死患者静脉注射茴香酰化纤溶酶原链激酶激活剂复合物或肝素后凝血与纤溶分析。一项比利时多中心研究。
Drugs. 1987;33 Suppl 3:253-60. doi: 10.2165/00003495-198700333-00047.
5
Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.茴香酰化纤溶酶原链激酶激活剂复合物和链激酶治疗急性心肌梗死的全身效应。荷兰侵入性再灌注研究的凝血方面。
Drugs. 1987;33 Suppl 3:242-6. doi: 10.2165/00003495-198700333-00045.
6
Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.对急性心肌梗死患者使用茴香酰化纤溶酶原链激酶激活剂复合物和链激酶的血液学影响。IRS II研究中期报告。
Drugs. 1987;33 Suppl 3:247-52. doi: 10.2165/00003495-198700333-00046.
7
An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).茴香酰化纤溶酶原链激酶激活剂复合物(APSAC)疗效与安全性的中期报告。
Drugs. 1987;33 Suppl 3:298-311. doi: 10.2165/00003495-198700333-00058.
8
Coagulation and fibrinolytic changes in evolving acute myocardial infarction treated by high-dose, brief-duration intracoronary or intravenous streptokinase.大剂量、短疗程冠状动脉内或静脉内注射链激酶治疗进展期急性心肌梗死时的凝血及纤溶变化
Am J Clin Pathol. 1990 Feb;93(2):246-51. doi: 10.1093/ajcp/93.2.246.
9
Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction.肝素治疗急性心肌梗死时不同链激酶治疗方案的药代动力学、溶栓疗效及出血风险
Am J Cardiol. 1989 May 15;63(17):1185-92. doi: 10.1016/0002-9149(89)90176-8.
10
Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.静脉注射茴香酰化纤溶酶原链激酶激活剂复合物或冠状动脉内注射链激酶治疗后的纤维蛋白原浓度与冠状动脉再灌注
Drugs. 1987;33 Suppl 3:237-41. doi: 10.2165/00003495-198700333-00044.

引用本文的文献

1
Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen.ST段抬高型心肌梗死患者的纤溶治疗:加速与标准链激酶输注方案对比
J Cardiovasc Thorac Res. 2017;9(4):209-214. doi: 10.15171/jcvtr.2017.36. Epub 2017 Dec 30.
2
Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.重编程的链激酶具有纤维蛋白靶向性,溶解血栓的效力比组织型纤溶酶原激活剂更强。
J Thromb Haemost. 2009 Aug;7(8):1321-8. doi: 10.1111/j.1538-7836.2009.03491.x. Epub 2009 Jun 30.
3
Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.
链激酶。老年患者急性心肌梗死中其药理学及治疗效果的综述
Drugs Aging. 1994 Jan;4(1):63-86. doi: 10.2165/00002512-199404010-00007.
4
Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.静脉注射链激酶。对其在急性心肌梗死治疗中的应用重新评估。
Drugs. 1990 May;39(5):693-719. doi: 10.2165/00003495-199039050-00006.